ArticleMolecular diagnosis & therapy2010
Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China.
Article in Molecular diagnosis & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- HIV-1 diversity and drug-resistant mutations in infected individuals in Changchun, China.PloS one · 2014Article
- Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa.Journal of the International AIDS Society · 2013Article
- Comparative evaluation of the ViroSeq™ HIV-1 genotyping system and an in-house method for analysis of HIV-1 drug-resistance mutations in China.Molecular diagnosis & therapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransmission of antiretroviral drug-resistant strains of HIV-1 has a major impact on the success of HIV treatment regimens in most countries where antiretroviral therapy (ART) is available. It is now recommended that HIV-1 drug resistance be monitored in order to recommend appropriate therapy for infected ART-naïve individuals, or when choosing a new regimen for those patients not responding to ART. Commercial assays for the analysis of HIV-1 genotypic resistance have been approved by the US FDA. In China, several laboratories and research enterprises have been developing related assays, but at present, no systematic standardization or quality control for genotypic resistance assays has been established in China. A national reference panel is needed to evaluate and control the quality of HIV-1 genotype resistance assays in China.
methodsA panel of five HIV-1 stocks (G1, G2, G3, G4, and G5) with well-characterized drug resistance was used to evaluate the resistance-mutation inclusivity of HIV-1 clades prevalent in China. Six samples (GS1-GS6) were used to evaluate the limit of detection (LOD) for the viral load levels, and five samples (GSS1-GSS3, GSS5, and GSS6) were used to evaluate the LOD for the percentages of mutant species within the range of detection. The samples were evaluated by five separate laboratories using one or two methods each, generating seven datasets in all.
resultsIn samples G1-G5, which were used to evaluate inclusivity of HIV-1 clades, 92.86-100%, 16.67-83.33% and 4.17-8.33% of the most, intermediately, and least common resistance mutations, respectively, were reported by the seven datasets. For the LOD samples, four of the seven datasets reported correct resistance mutations in samples with minimal viral loads of >2 x 10(3) copies/mL, as well as in samples with >40% of mutants and viral loads of about 1 x 10(4) copies/mL; the other three tests did not amplify the target region or identify the mutants.
conclusionsThe results were quite variable between different tests. The panel of HIV-1 genotypic resistance could be used as a control for resistance testing in China.
Indexed as
Identifiers
20121288What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.